HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER Russian patent published in 2024 - IPC C12N7/01 A61K35/763 C12N15/00 

FIELD: biotechnology.

SUBSTANCE: described is a non-natural herpes simplex virus (HSV) for treating cancer, comprising one or more mutations in a gene coding glycoprotein E (gE), wherein the mutation codes a mutation of alanine to threonine at position 151 of the gE protein. Also described is a composition for treating cancer, containing unnatural HSV and a carrier, such as a pharmaceutically acceptable carrier. Disclosed is a non-human mammal for treating cancer infected with unnatural HSV. Described is a cell for treating cancer, infected with unnatural HSV. Disclosed is a method of infecting a cell or inducing cell lysis, involving bringing the cell into contact with a non-natural HSV or composition. Disclosed is a method for producing a viral vector involving the introduction of a transgene into a non-natural HSV. Described is a method of inhibiting growth or metastasis of a cancer cell, involving contacting the cell with an effective amount of a non-natural HSV or composition. Disclosed is a method of treating cancer in a subject, wherein the method involves administering an effective amount of a non-natural HSV or composition to the subject. Described is a method of producing HSV, comprising (a) introducing 17TermA HSV and rRp450 HSV into a host cell; (b) growing a host cell in at least 3 passages; and (c) recovering the HSV particle produced by the host cell. Disclosed is an HSV particle for treating cancer, obtained by the method. Disclosed is a method of producing HSV according to any one of claims 1–5, including: (a) introducing into a host cell a polynucleotide coding the HSV viral genome; (b) growing a host cell; and (c) recovering the HSV particle produced by the host cell.

EFFECT: invention extends the range of products for treating cancer.

21 cl, 5 dwg, 1 tbl